{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:11:40Z","timestamp":1783973500541,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbih.2026.101277","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:12:46Z","timestamp":1780531966000},"page":"101277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Celecoxib adjunct to antidepressants for major depressive disorder: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-1206","authenticated-orcid":false,"given":"Manit","family":"Srisurapanont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawisa","family":"Suradom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirijit","family":"Suttajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2026.101277_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbih.2026.101277_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/da.20589","article-title":"Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.bbih.2026.101277_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13524","article-title":"Empirical assessment of prediction intervals in Cochrane meta-analyses","volume":"51","author":"Al Amer","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbih.2026.101277_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fpsyt.2019.00458","article-title":"Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium","volume":"10","author":"Arteaga-Henr\u00edquez","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101277_bib5","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/genes12111758","article-title":"The nifluence of CYP2D6 and CYP2C19 genetic variation on diabetes mellitus risk in people taking antidepressants and antipsychotics","volume":"12","author":"Austin-Zimmerman","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.bbih.2026.101277_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Base Ment. Health"},{"key":"10.1016\/j.bbih.2026.101277_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.bbih.2026.101277_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2021.07.092","article-title":"No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: a 6-week double-blind placebo controlled randomized trial","volume":"53","author":"Baune","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbih.2026.101277_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/YCO.0000000000000976","article-title":"The role of immunomodulators in severe mental disorders: future perspectives","volume":"38","author":"Baune","year":"2025","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101277_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.bbih.2026.101277_bib11","article-title":"Introducing prediction intervals for sample means","volume":"34","author":"Contini","year":"2024","journal-title":"Biochem. Med."},{"key":"10.1016\/j.bbih.2026.101277_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbih.2026.101277_bib13","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/jcm12103497","article-title":"Celecoxib for mood disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"G\u0119dek","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbih.2026.101277_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.bbih.2026.101277_bib15","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt","year":"2025","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbih.2026.101277_bib16","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.bbih.2026.101277_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbih.2026.101277_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The hartung-knapp-sidik-jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.bbih.2026.101277_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamapsychiatry.2025.0206","article-title":"Should inflammation be a specifier for major depression in the DSM-6?","volume":"82","author":"Jha","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature","volume":"242","author":"Johnston","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbih.2026.101277_bib21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/jnc.15946","article-title":"Inflammation-stratified augmentation of vortioxetine with celecoxib: results from a double-blind, randomized, placebo-controlled trial in major depressive disorder","volume":"168","author":"Kavakbasi","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbih.2026.101277_bib24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","article-title":"Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials","volume":"71","author":"K\u00f6hler","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s40501-022-00267-1","article-title":"Repurposing anti-inflammatory agents for mood disorders: an updated review of current evidence","volume":"9","author":"Kittur","year":"2022","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib23","series-title":"Mkinfer: Inferential Statistics","author":"Kohl","year":"2024"},{"key":"10.1016\/j.bbih.2026.101277_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.ajp.20241115","article-title":"Effect of anti-inflammatory treatment on depressive symptom severity and anhedonia in depressed individuals with elevated inflammation: systematic review and meta-analysis of randomized controlled trials","volume":"183","author":"Mac Giollabhui","year":"2026","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib26","first-page":"891","article-title":"A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study","volume":"14","author":"Majd","year":"2015","journal-title":"Iran. J. Pharm. Res. IJPR"},{"key":"10.1016\/j.bbih.2026.101277_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1037\/a0017336","article-title":"Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis","volume":"24","author":"McClintock","year":"2010","journal-title":"Neuropsychology"},{"key":"10.1016\/j.bbih.2026.101277_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbih.2026.101277_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41380-022-01887-y","article-title":"Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies","volume":"28","author":"Miller","year":"2023","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101277_bib30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"M\u00fcller","year":"2006","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101277_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pnpbp.2013.09.006","article-title":"Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib32","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1017\/S0033291719001454","article-title":"Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels","volume":"49","author":"Osimo","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bbih.2026.101277_bib33","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbih.2026.101277_bib34","series-title":"R: a Language and Environment for Statistical Computing","year":"2025"},{"key":"10.1016\/j.bbih.2026.101277_bib35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\u2217D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/00912174231210567","article-title":"The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder","volume":"59","author":"Sakhvidi","year":"2024","journal-title":"Int. J. Psychiatr. Med."},{"key":"10.1016\/j.bbih.2026.101277_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.bbih.2026.101277_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S385117","article-title":"Anti-inflammatory treatment efficacy in major depressive disorder: a systematic review of meta-analyses","volume":"19","author":"Simon","year":"2023","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.bbih.2026.101277_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.615261","article-title":"Efficacy of sertraline plus placebo or add-On celecoxib in major depressive disorder: macrophage migration inhibitory factor as a promising biomarker for remission after sertraline-results from a randomized controlled clinical trial","volume":"12","author":"Simon","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.bbih.2026.101277_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00004714-199704000-00007","article-title":"CYP2D6 inhibition in patients treated with sertraline","volume":"17","author":"Sproule","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbih.2026.101277_bib41","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbih.2026.101277_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2147\/NDT.S114542","article-title":"Biomarkers for depression: recent insights, current challenges and future prospects","volume":"13","author":"Strawbridge","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.bbih.2026.101277_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjos-2020-100074","article-title":"Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research","volume":"5","author":"Tanriver-Ayder","year":"2021","journal-title":"BMJ Open Sci."},{"key":"10.1016\/j.bbih.2026.101277_bib44","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/npp.2014.9","article-title":"Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users","volume":"39","author":"Vogelzangs","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbih.2026.101277_bib45","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.12998\/wjcc.v10.i22.7872","article-title":"Effect of celecoxib on improving depression: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bbih.2026.101277_bib46","article-title":"Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial","volume":"41","author":"Wessa","year":"2024","journal-title":"Brain Behav. Immun. - Health"},{"key":"10.1016\/j.bbih.2026.101277_bib47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2215-0366(25)00308-6","article-title":"Anti-inflammatories for depression: challenges and ASPIRations","volume":"13","author":"Worrell","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bbih.2026.101277_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2025.02.053","article-title":"Exploring the potential antidepressant mechanisms of ibuprofen and celecoxib based on network pharmacology and molecular docking","volume":"377","author":"Zhang","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbih.2026.101277_bib49","article-title":"Efficacy of celecoxib add-on treatment for immuno-metabolic depression: protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial","volume":"27","author":"Zwiep","year":"2023","journal-title":"Brain Behav. Immun. - Health"}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354626001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:02:31Z","timestamp":1783972951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354626001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"alternative-id":["S2666354626001109"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101277","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celecoxib adjunct to antidepressants for major depressive disorder: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2026.101277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101277"}}